Oral Genome has partnered with Henry Schein to distribute its point-of-care saliva testing kits to dental and medical practices across the United States.
Oral Genome announced a strategic partnership with Henry Schein to bring its saliva testing technology to dental and medical practices nationwide. The collaboration aims to integrate point-of-care testing into more offices to support the connection between oral and systemic health.
Saliva Testing in 15 Minutes
Oral Genome’s saliva test kits are performed chairside and reportedly deliver results in 15 minutes. The accompanying software analyzes biomarkers in saliva, providing a real-time look at oral and overall health. By connecting with Henry Schein’s distribution network, the Oral Genome expects to give dental professionals tools to identify health concerns earlier and strengthen patient relationships.
Company Leaders on the Partnership
“We’re thrilled to join forces with Henry Schein to support providers bridging the gap between dental and medical care,” said Dr Tina Saw, CEO of Oral Genome. “Our point-of-care testing equips practitioners with actionable insights, transforming routine visits into opportunities for whole-health advocacy.”
“Henry Schein is committed to bringing advanced solutions that enhance patient outcomes to our customers,” said Dirk Benson, president of Henry Schein’s U.S. Distribution Group. “Expanded point of care testing offerings align with our mission to advance prevention and wellness through systemic health models, and Oral Genome offers dentists and physicians a powerful tool to elevate care.”
Distribution and Target Markets
The rollout will occur through Henry Schein’s distribution channels. Target markets include dental practices, community health clinics, and medical offices interested in new preventive care methods. Both companies have emphasized their commitment to advancing health care through technology and collaboration.
Photo: Henry Schein
